Multiple cellular consequences of isocitrate dehydrogenase isozyme dysfunction.

Arch Biochem Biophys

Department of Biochemistry, University of Texas Health Science Center, San Antonio, TX 78229, USA.

Published: November 2003

To probe the functions of multiple forms of isocitrate dehydrogenase in Saccharomyces cerevisiae, mutants lacking three of the isozymes were constructed and analyzed. Results show that, while the mitochondrial NAD+-dependent enzyme, IDH (composed of Idh1p and Idh2p subunits) is not the major contributor to total isocitrate dehydrogenase activity under any growth condition, loss of IDH produces the most dramatic growth phenotypes. These include reduced growth in the absence of glutamate, as well as an increase in expression of Idp2p (the cytosolic NADP+-dependent enzyme) under some growth conditions. In this study, we have focused on another phenotype associated with loss of IDH, an elevated frequency of petite mutations indicating loss of functional mtDNA. Using mutant forms of IDH with altered active site residues, a correlation was observed between the high frequency of petite mutations and the loss of catalytic activity. Loss of Idp1p (the mitochondrial NADP+-dependent enzyme) and Idp2p contributes to the loss of functional mtDNA, but only in an IDH dysfunctional background. Surprisingly, overexpression of Idp1p, but not of Idp2p, was found to result in an elevated petite frequency independent of the functional state of IDH. This is the first phenotype associated with altered Idp1p. Finally, throughout this study we examined effects of loss of mitochondrial citrate synthase (Cit1p) on isocitrate dehydrogenase mutants, since defects in the CIT1 gene were previously shown to enhance growth of IDH dysfunctional strains on nonfermentable carbon sources. Loss of Cit1p was found to suppress the petite phenotype of strains lacking IDH, suggesting that these phenotypes may be linked.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.abb.2003.08.022DOI Listing

Publication Analysis

Top Keywords

isocitrate dehydrogenase
16
idh
8
loss
8
loss idh
8
nadp+-dependent enzyme
8
phenotype associated
8
frequency petite
8
petite mutations
8
loss functional
8
functional mtdna
8

Similar Publications

Karnofsky Performance Status (KPS) is a widely used scale to assess performance status. KPS ≥ 50% implies that patients can live at home. Therefore, maintaining KPS ≥ 50% is important to improve the quality of life of patients with glioblastoma, whose median survival is less than 2 years.

View Article and Find Full Text PDF

Background/objectives: In the REGOMA trial, regorafenib demonstrated an overall survival advantage over lomustine, and it has become a recommended treatment for recurrent glioblastoma in guidelines. This study aimed to evaluate the effectiveness and safety of regorafenib as a third-line treatment for patients with recurrent glioblastoma who progressed while taking bevacizumab-based therapy.

Methods: This retrospective, multicenter study in Turkey included 65 patients treated between 2021 and 2023 across 19 oncology centers.

View Article and Find Full Text PDF

Purpose: Glioblastomas contacting the subventricular zone (SVZ) are associated with poor prognosis and the impact of ventricular entry (VE) during resection remains controversial. Since glioblastomas with SVZ involvement often require VE, both SVZ involvement and VE are confounding factors. This study aimed to evaluate the effect of VE during glioblastoma resection by comparing patients with and without SVZ involvement.

View Article and Find Full Text PDF

Malignant gliomas are heterogeneous tumors, mostly incurable, arising in the central nervous system (CNS) driven by genetic, epigenetic, and metabolic aberrations. Mutations in isocitrate dehydrogenase (IDH1/2) enzymes are predominantly found in low-grade gliomas and secondary high-grade gliomas, with IDH1 mutations being more prevalent. Mutant-IDH1/2 confers a gain-of-function activity that favors the conversion of a-ketoglutarate (α-KG) to the oncometabolite 2-hydroxyglutarate (2-HG), resulting in an aberrant hypermethylation phenotype.

View Article and Find Full Text PDF

Deep learning MRI models for the differential diagnosis of tumefactive demyelination versus -wildtype glioblastoma.

AJNR Am J Neuroradiol

January 2025

From the Department of Radiology (GMC, MM, YN, BJE), Department of Quantitative Health Sciences (PAD, MLK, JEEP), Department of Neurology (CBM, JAS, MWR, FSG, HKP, DHL, WOT), Department of Neurosurgery (TCB), Department of Laboratory Medicine and Pathology (RBJ), and Center for Multiple Sclerosis and Autoimmune Neurology (WOT), Mayo Clinic, Rochester, MN, USA; Dell Medical School (MFE), University of Texas, Austin, TX, USA.

Background And Purpose: Diagnosis of tumefactive demyelination can be challenging. The diagnosis of indeterminate brain lesions on MRI often requires tissue confirmation via brain biopsy. Noninvasive methods for accurate diagnosis of tumor and non-tumor etiologies allows for tailored therapy, optimal tumor control, and a reduced risk of iatrogenic morbidity and mortality.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!